Influenza A virus H1N1 vaccine - sanofi pasteur

Drug Profile

Influenza A virus H1N1 vaccine - sanofi pasteur

Alternative Names: Humenza; Inactivated H1N1 vaccine - sanofi pasteur; Influenza A (H1N1) 2009 monovalent vaccine, adjuvanted - sanofi pasteur; Influenza A (H1N1) 2009 monovalent vaccine, non-adjuvanted - sanofi pasteur; Influenza A(H1N1) monovalent vaccine - sanofi pasteur; Pandemic influenza vaccine (H1N1) split virion; Panenza; Swine flu vaccine - sanofi pasteur

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi pasteur
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H1N1 subtype

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype (Prevention) in Brazil (IM, Injection)
  • 06 Mar 2014 Discontinued - Registered for Influenza-A virus H1N1 subtype in European Union (IM, adjuvanted)
  • 06 Mar 2014 Withdrawn for Influenza-A virus H1N1 subtype in Poland (IM, adjuvanted)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top